Michel R Langlois1,2, Børge G Nordestgaard3. 1. AZ St.-Jan Hospital, Department of Laboratory Medicine, Ruddershove 10, 8000, Brugge, Belgium. michel.langlois@azsintjan.be. 2. University of Ghent, Ghent, Belgium. michel.langlois@azsintjan.be. 3. Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.
Abstract
PURPOSE OF REVIEW: To summarize and discuss the clinical use of lipid and apolipoprotein tests in the settings of diagnosis and therapeutic follow-up of hyperlipidemia. RECENT FINDINGS: The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently produced recommendations on the measurement of atherogenic lipoproteins, taking into account the strengths and weaknesses of analytical and clinical performances of the tests. Total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and calculated non-HDL cholesterol (= LDL + remnant cholesterol) constitute the primary lipid panel for hyperlipidemia diagnosis and cardiovascular risk estimation. LDL cholesterol is the primary target of lipid-lowering therapies. Non-HDL cholesterol or apolipoprotein B should be used as secondary therapeutic target in patients with mild-to-moderate hypertriglyceridemia, 2-10 mmol/l (175-880 mg/dl). Lipoprotein (a) is included in LDL cholesterol and should be measured at least once in all patients at cardiovascular risk, including to explain poor response to statin treatment.
PURPOSE OF REVIEW: To summarize and discuss the clinical use of lipid and apolipoprotein tests in the settings of diagnosis and therapeutic follow-up of hyperlipidemia. RECENT FINDINGS: The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently produced recommendations on the measurement of atherogenic lipoproteins, taking into account the strengths and weaknesses of analytical and clinical performances of the tests. Total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and calculated non-HDL cholesterol (= LDL + remnant cholesterol) constitute the primary lipid panel for hyperlipidemia diagnosis and cardiovascular risk estimation. LDL cholesterol is the primary target of lipid-lowering therapies. Non-HDL cholesterol or apolipoprotein B should be used as secondary therapeutic target in patients with mild-to-moderate hypertriglyceridemia, 2-10 mmol/l (175-880 mg/dl). Lipoprotein (a) is included in LDL cholesterol and should be measured at least once in all patients at cardiovascular risk, including to explain poor response to statin treatment.
Authors: Vasanth Sathiyakumar; Jihwan Park; Asieh Golozar; Mariana Lazo; Renato Quispe; Eliseo Guallar; Roger S Blumenthal; Steven R Jones; Seth S Martin Journal: Circulation Date: 2017-10-16 Impact factor: 29.690
Authors: James D Otvos; Samia Mora; Irina Shalaurova; Philip Greenland; Rachel H Mackey; David C Goff Journal: J Clin Lipidol Date: 2011 Mar-Apr Impact factor: 4.766
Authors: Thomas G Cole; John H Contois; Gyorgy Csako; Joseph P McConnell; Alan T Remaley; Sridevi Devaraj; Daniel M Hoefner; Tonya Mallory; Amar A Sethi; G Russell Warnick Journal: Clin Chem Date: 2013-02-05 Impact factor: 8.327
Authors: Michel R Langlois; Olivier S Descamps; Arnoud van der Laarse; Cas Weykamp; Hannsjörg Baum; Kari Pulkki; Arnold von Eckardstein; Dirk De Bacquer; Jan Borén; Olov Wiklund; Païvi Laitinen; Wytze P Oosterhuis; Christa Cobbaert Journal: Atherosclerosis Date: 2014-01-04 Impact factor: 5.162
Authors: Michael G Silverman; Brian A Ference; Kyungah Im; Stephen D Wiviott; Robert P Giugliano; Scott M Grundy; Eugene Braunwald; Marc S Sabatine Journal: JAMA Date: 2016-09-27 Impact factor: 56.272
Authors: S Matthijs Boekholdt; Benoit J Arsenault; G Kees Hovingh; Samia Mora; Terje R Pedersen; John C Larosa; K M A Welch; Pierre Amarenco; David A Demicco; Andrew M Tonkin; David R Sullivan; Adrienne Kirby; Helen M Colhoun; Graham A Hitman; D John Betteridge; Paul N Durrington; Michael B Clearfield; John R Downs; Antonio M Gotto; Paul M Ridker; John J P Kastelein Journal: Circulation Date: 2013-08-21 Impact factor: 29.690
Authors: Albert Wiegman; Samuel S Gidding; Gerald F Watts; M John Chapman; Henry N Ginsberg; Marina Cuchel; Leiv Ose; Maurizio Averna; Catherine Boileau; Jan Borén; Eric Bruckert; Alberico L Catapano; Joep C Defesche; Olivier S Descamps; Robert A Hegele; G Kees Hovingh; Steve E Humphries; Petri T Kovanen; Jan Albert Kuivenhoven; Luis Masana; Børge G Nordestgaard; Päivi Pajukanta; Klaus G Parhofer; Frederick J Raal; Kausik K Ray; Raul D Santos; Anton F H Stalenhoef; Elisabeth Steinhagen-Thiessen; Erik S Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen; Olov Wiklund Journal: Eur Heart J Date: 2015-05-25 Impact factor: 29.983
Authors: Robert S Rosenson; Terry A Jacobson; David Preiss; C Stephen Djedjos; Ricardo Dent; Ian Bridges; Michael Miller Journal: Cardiovasc Drugs Ther Date: 2016-06 Impact factor: 3.727
Authors: Raimund Pechlaner; Sotirios Tsimikas; Xiaoke Yin; Peter Willeit; Ferheen Baig; Peter Santer; Friedrich Oberhollenzer; Georg Egger; Joseph L Witztum; Veronica J Alexander; Johann Willeit; Stefan Kiechl; Manuel Mayr Journal: J Am Coll Cardiol Date: 2017-02-21 Impact factor: 24.094